-
1.发明公开시닥나무 추출물을 함유하는 에이디피-리보실 사이클라제 활성을 저해하는 억제제 无效ADP-RIBOSYL CYCLASES的激活包括ACER TSCHONOSKII VAR的提取物的抑制剂。 红鳍东方鲀
公开(公告)号：KR1020110133329A
公开(公告)日：2011-12-12
申请号：KR1020100053000
申请日：2010-06-04
Applicant: 전북대학교산학협력단
Abstract: PURPOSE: An ADP-ribosyl cyclase containing Acer komarovii extract is provided to suppress intracellular calcium increase and to treat diseases caused by intracellular abnormal calcium increase. CONSTITUTION: An ADPR-cyclase inhibitor contains Acer komarovii extract. A therapeutic agent for preventing and treating liver diseases induced by liver tissue selective ADPR-cyclase activity contains Acer komarovii extract. The Acer komarovii extract is administered in an oral or parenteral formulation. A solid formulation for oral administration includes a tablet, pill, powder, granule, capsule, and troche. The liquid formulation for oral administration contains suspension, oil, or syrup. The daily dose of the Acer komarovii extract is 1-1,000 mg/day.
Abstract translation: 目的：提供含有Acer komarovii提取物的ADP-核糖基环化酶，以抑制细胞内钙的增加和治疗由细胞内异常钙增加引起的疾病。 构成：ADPR环化酶抑制剂含有宏碁提取物。 用于预防和治疗由肝组织选择性ADPR-环化酶活性诱导的肝病的治疗剂含有宏碁提取物。 宏碁提取物以口服或肠胃外制剂给药。 用于口服给药的固体制剂包括片剂，丸剂，粉剂，颗粒剂，胶囊剂和锭剂。 用于口服给药的液体制剂含有悬浮液，油或糖浆。 Acer komarovii提取物的日剂量为1-1000mg /天。
-
公开(公告)号：KR100931997B1
公开(公告)日：2009-12-15
申请号：KR1020080007281
申请日：2008-01-23
Applicant: 한국생명공학연구원 , 전북대학교산학협력단
Abstract: 본 발명은 간세포암 종양 마커로서의 KLK-5 및 이를 이용한 간세포암의 진단 방법에 관한 것이다. 또한 상기 간세포암 종양 마커의 존재를 측정하는 제제를 포함하는 간세포암 진단용 조성물 및 키트에 관한 것이다.
간세포암, 진단, 표지자, 키트Abstract translation: 本发明涉及作为肝细胞癌肿瘤标志物的KLK-5和使用其的肝细胞癌的诊断方法。 并用于测量肝细胞癌肿瘤标志物的存在。
-
公开(公告)号：KR1020090081289A
公开(公告)日：2009-07-28
申请号：KR1020080007281
申请日：2008-01-23
Applicant: 한국생명공학연구원 , 전북대학교산학협력단
CPC classification number: C12N15/11 , C12Q1/6886 , C12Q2600/118 , C12Q2600/156
Abstract: A KLK gene as a tumor marker and method for diagnosing hepatocellular carcinoma are provided to obtain a novel diagnosis marker and research specific anticancer drug. A method for diagnosing hepatocellular carcinoma comprises: a step of measuring level of KLK-5 gene from a biological sample isolated from a patient with suspected hepatocellular carcinoma and protein level of the gene; and a step of comparing the expression levels of gene and protein between normal control sample and patient sample.
Abstract translation: 提供KLK基因作为肿瘤标志物和诊断肝细胞癌的方法，以获得新的诊断标志物和研究特异性抗癌药物。 一种诊断肝细胞癌的方法，包括：从疑似肝细胞癌患者和基因蛋白水平分离的生物样品中测定KLK-5基因水平的步骤; 以及比较正常对照样品和患者样品之间的基因和蛋白质的表达水平的步骤。
-
4.发明公开
公开(公告)号：KR1020080061431A
公开(公告)日：2008-07-03
申请号：KR1020060135890
申请日：2006-12-28
Applicant: 전북대학교산학협력단
IPC: C07C245/08 , C07C245/06 , C07C15/52
CPC classification number: C07C245/08 , C07C39/215
Abstract: A bisphenyl derivative is provided to obtain an ADP-ribosyl cyclase inhibitor having selectivity to each tissue cell and useful for preventing and/or treating cardiac, renal or cerebral diseases. A bisphenyl derivative is represented by the following formula 1. In formula 1, X and Y are linked to each other via a single bond or double bond, and each represents carbon, nitrogen, sulfur or oxygen; and each of R1, R2, R3, R4, R5, R6, R7, R8, R9 and R10 is selected from the group consisting of hydroxyl(OH), hydrogen(H), amine(-NH2), amide(-NH), nitro(-NO2), nitroso(-NO), carboxyl(-COOH), aldehyde(-CHO), carbonyl(-C=O), sulfhydryl(-SH) and sulfoxyl(-SO3H).
Abstract translation: 提供双苯衍生物以获得对每个组织细胞具有选择性并可用于预防和/或治疗心脏，肾或脑疾病的ADP-核糖基环化酶抑制剂。 双苯衍生物由下式1表示。在式1中，X和Y通过单键或双键彼此连接，各自表示碳，氮，硫或氧; 并且R 1，R 2，R 3，R 4，R 5，R 6，R 7，R 8，R 9和R 10各自选自羟基（OH），氢（H），胺（-NH 2），酰胺 ，硝基（-NO 2），亚硝基（-NO），羧基（-COOH），醛（-CHO），羰基（-C = O），巯基（-SH）和亚磺酰基（-SO 3 H）。
-
公开(公告)号：KR1020170058092A
公开(公告)日：2017-05-26
申请号：KR1020150161877
申请日：2015-11-18
Applicant: 김선영 , 전북대학교산학협력단
Abstract: 본발명은, 도로(200)를주행하는차량(100)에구비된충전제어장치로서, 상기차량(100)의엔진동력에의해구동되어교류발전하는교류발전기(110); 상기교류발전기(110)로부터제공되는교류를직류로변환하여상기차량(100)의각 전자기기로출력하는교류-직류변환부(120); 상기교류-직류변환부(120)로부터제공되는직류를충전하고엔진시동시 스타트모터를구동시킬직류를출력하기위한배터리(130); 상기차량(100)의앞쪽도로(200) 표면을레이저스캔하는레이저스캔부(140); 상기차량(100)의경사도를검출하는경사도검출부(150); 상기교류-직류변환부(120)의직류가상기배터리(130)로제공되는것을단속하는스위칭부(160); 및상기레이저스캔부(140)로부터제공되는상기앞쪽도로(200) 표면스캔정보와상기경사도검출부(150)로부터제공되는상기차량(100)의경사도정보로부터상기앞쪽도로(200) 표면에설정치이상요철이있거나설정치이상경사져있다고판단될경우상기스위칭부(160)를제어하여상기교류-직류변환부(120)의직류가상기배터리(130)로제공되는것을차단시키는충전제어부(170); 를포함하는것을특징으로한다.
Abstract translation: 本发明提供的车辆100 Eguzemodo未填充控制装置，沿着道路200行驶时，车辆交流发电机110由发动机的交流发电的电力来驱动（100）; 其转换来自交流发电机110在电子设备uigak-DC转换器120提供到DC至AC输出到车辆100中的交变电流; 电池130，用于在发动机起动时对从AC-DC转换器120供应的DC进行充电并输出DC以驱动起动马达; 激光扫描单元140，用于激光扫描车辆100前方的道路200的表面; 用于检测车辆100的散光程度的倾斜度检测单元150; 开关单元160，用于控制AC-DC转换器120的直流电流供应给电池130; 并且，从激光扫描单元140提供的前方道路200扫描表面信息和从倾斜度检测单元150提供的车辆100的路面度信息， 或者如果判断为通过控制开关单元160在AC充电控制单元170以阻断直流转换器120的直流倾斜大于设定值更其中电池130玫瑰球; [0015]
-
Patent Agency Ranking
公开(公告)号：KR1020110121019A
公开(公告)日：2011-11-07
申请号：KR1020100040417
申请日：2010-04-30
Applicant: 전북대학교산학협력단
IPC: A61K31/517 , A61P9/00
CPC classification number: A61K31/517 , A61K9/02 , A61K9/10 , A61K9/20
Abstract: PURPOSE: A quinazoline derivative which controls the activity of ADP-ribosyl cyclase(ADPR-cyclase) is provided to suppress intracellular calcium increase. CONSTITUTION: An ADPR-cyclase inhibitor contains quinazoline derivatives of chemical formula 1. In chemical formula 1, R1, R2, R3, R4, and R5 are hydrogen, halogen atoms, low alkyl group of 1-6 carbon atoms. The derivative of chemical formula 1 is 6,8-dimehty-N-[1-(naphthalene-1-yl)ethyl]quinazoline-1-amine. An agent of preventing and treating kidney and cardiovascular diseases contains the quinazoline derivative of chemical formula 1.
Abstract translation: 目的：提供控制ADP-核糖基环化酶（ADPR-环化酶）活性的喹唑啉衍生物，以抑制细胞内钙的增加。 构成：ADPR环化酶抑制剂含有化学式1的喹唑啉衍生物。在化学式1中，R 1，R 2，R 3，R 4和R 5为氢，卤素原子，1-6个碳原子的低级烷基。 化学式1的衍生物是6,8-二甲基-N- [1-（萘-1-基）乙基]喹唑啉-1-胺。 预防和治疗肾脏和心血管疾病的药物含有化学式1的喹唑啉衍生物。
-
公开(公告)号：KR1020110054409A
公开(公告)日：2011-05-25
申请号：KR1020090111031
申请日：2009-11-17
Applicant: 전북대학교산학협력단 , 임실생약영농조합법인
IPC: A61K36/539 , A61P25/32 , A61K36/288 , A61K36/185
Abstract: PURPOSE: A hangover-relieving agent containing flavonoid is provided to suppress ROS generation and to prevent apoptosis of hepatocytes. CONSTITUTION: A hangover-relieving agent containing flavonoid is prepared by adding 1-10 weight% of taurine to extract mixture of 5-10 weight% of Scutellaria baicalensis, 5-10 weight% of Taraxacum platycarpum, 10-20 weight% of Alnus japonica Steude, 5-15 weight% of Puerariae radix, 1-10 weight% of red ginseng, 1-10 weight% of malt, 1-10 weight% of Aurantii nobilis Pericarpium, 1-10 weight parts of Artemisiae capillaries herba, 1-5 weight% of Atractylodes macrocephala Koidzumi, and 1-5 weight% of Beckmannia syzigachne.
Abstract translation: 目的：提供含有类黄酮的宿醉缓解剂，以抑制ROS的产生并防止肝细胞凋亡。 构成：通过添加1-10重量％的牛磺酸来提取5-10重量％的黄芩，5-10重量％的蒲公英，10-20重量％的Al粳的混合物，制备含有黄酮的宿醉缓释剂 葛根5-15重量％，红参1-10重量％，麦芽1-10重量％，天竺葵1-10重量％，蒿青蒿1-10重量份， 5％（重量）白术（Atractylodes macrocephala Koidzumi）和1-5％（重量）的贝克曼氏菌属。
-
公开(公告)号：KR102249761B1
公开(公告)日：2021-05-11
申请号：KR1020190123918
申请日：2019-10-07
Applicant: 전북대학교산학협력단 , 주식회사 세자
Abstract: 본발명은이동거리가변형마사지건에관한것으로서, 특히인체에충돌하여가하는힘의세기를조절할수 있는이동거리가변형마사지건에관한것이다. 본발명의이동거리가변형마사지건은, 전방에직선가이드부가형성된베이스부재와; 상기베이스부재에장착된모터와; 상기모터의회전축에연결되어회전하는디스크캠과; 상기베이스부재에서상기직선가이드부를따라직선이동가능하게장착된피스톤과; 상기피스톤의일단에결합된프런트볼과; 일단이상기디스크캠에회전가능하게결합되고, 타단이상기피스톤의타단에결합된커넥팅로드와; 상기커넥팅로드의일단을상기디스크캠에결합시키는제1결합핀과; 상기커넥팅로드의타단을상기피스톤에결합시키는제2결합핀;을포함하여이루어지되, 상기모터의구동에의한상기디스크캠의회전시상기커넥팅로드는상기디스크캠의회전운동을직선운동으로변환시키면서상기피스톤을전후방향으로왕복운동시키며, 상기디스크캠에는원호형상의장착공이형성되고, 상기제1결합핀은상기장착공에삽입되어상기커넥팅로드의일단과결합되며, 원호형상의상기장착공은일단이상기디스크캠의회전중심에인접하고, 타단이상기디스크캠의회전중심에서일단보다먼거리에위치하고있는것을특징으로한다.
-
公开(公告)号：KR101467996B1
公开(公告)日：2014-12-11
申请号：KR1020100040417
申请日：2010-04-30
Applicant: 전북대학교산학협력단
IPC: A61K31/517 , A61P9/00
Abstract: 본발명은에이디피-리보실사이클레이즈 (ADPR-cyclase)의활성을조절하는퀴나졸린유도체에관한것으로, 구체적으로퀴나졸린유도체를유효성분으로하는선택적 ADPR-cyclase 억제제및 ADPR-cyclase 활성에의한세포내칼슘증가억제제에관한것이다. 상기퀴나졸린유도체는 ADPR-cyclase 효소및 세포내칼슘증가를억제함으로써, 심장, 신장및 뇌질환등의세포내비정상적인칼슘증가로유발되는질병치료에도사용될수 있다.
-
公开(公告)号：KR1020110133345A
公开(公告)日：2011-12-12
申请号：KR1020100053020
申请日：2010-06-04
Applicant: 전북대학교산학협력단
IPC: A61K36/282 , A61P13/12 , A61P25/00
Abstract: PURPOSE: An inhibitor containing Artemisia scoparia Waldst. Et Kitaib. extract is provided to suppress intracellular calcium increase. CONSTITUTION: An ADPR-cyclase inhibitor contains Artemisia scoparia Waldst. Et Kitaib. extract. An agent for preventing and treating renal and cardiovascular diseases induced by ADPR-cyclase activity contains the Artemisia scoparia Waldst. Et Kitaib. extract. The Artemisia scoparia Waldst. Et Kitaib. extract is administered by oral formulation and parenteral formulation in case of clinical administration. The daily dose of the Artemisia scoparia Waldst. Et Kitaib. extract is 1-1000 mg/day.
Abstract translation: 目的：含有青蒿的抑制剂。 Et Kitaib 提供提取物以抑制细胞内钙的增加。 构成：ADPR环化酶抑制剂含有蒿草。 Et Kitaib 提取。 用于预防和治疗由ADPR-环化酶活性诱导的肾脏和心血管疾病的药物含有青蒿（Waldst）。 Et Kitaib 提取。 艾蒿 Et Kitaib 提取物在临床给药的情况下通过口服制剂和肠胃外制剂施用。 艾蒿的日剂量Waldst。 Et Kitaib 提取物为1-1000mg /天。
-
-
-
-
-
-
-
-
-
Search Results
14
records
(took 0.019 seconds)
